Table 1 IC50s of oxaliplatin in HCT116 and A549 cancer cells in the absence and presence of WLR treatment
Treatment | IC50s (μg/mL) | |
|---|---|---|
HCT116 | A549 | |
L-OHP | 1.05 ± 0.07 | 6.94 ± 0.78 |
L-OHP + Vehicle | 0.97 ± 0.01 | 5.83 ± 0.02 |
L-OHP + WLR (10 μg/mL) | 0.98 ± 0.06 | 6.76 ± 0.00 |
L-OHP + WLR (30 μg/mL) | 1.00 ± 0.02 | 7.66 ± 1.25 |
L-OHP + WLR (100 μg/mL) | 0.98 ± 0.02 | 6.50 ± 0.30 |